PharmaCielo Ltd

The CIN framework assigns Pharmacielo Ltd. a Neutral rating at 39/100, with conviction of 3 out of 5. The composite is a fixed blend of four pillars — fundamentals at 35 percent, regulatory at 25, market at 25, and editorial at 15 — and each contribution is inspectable. The strongest contribution comes from the regulatory pillar at 58, and pulls the composite toward the lower edge of the band. Fundamentals lags at 29, softening what would otherwise be a stronger reading.

Under the hood, the data points sit as follows: reported revenue growth of -46.2 percent year over year, an operating margin of 262.3 percent, gross margin of -17.7 percent. Each of those figures ties back to a specific input in the pillar breakdown. Every input flowing into the pillar table comes from primary regulatory filings, licensed fundamentals data, and institutional pricing feeds, filtered through CIN newsroom density. The 336-ticker CIN universe is scored deterministically, so Pharmacielo Ltd. can be compared against the global cannabis coverage universe on identical inputs, refreshed on the ingest cycle.

The rating turns on regulatory pace. Filings landing at above the trailing-90-day cadence, combined with an unblemished enforcement record, would carry Pharmacielo Ltd. above the Neutral anchor; a lull would soften the read.